SCHEMBL10139872

SCHEMBL10139872

COc1c(-c2ccc(Cl)cc2)nn(C)c1-c1nc2ccc(C#N)cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.46
PKN1 Q16512 1/20 0.46
PKN2 Q16513 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.45
RHEB Q15382 1/20 0.43
HIF1A Q16665 1/20 0.43
AMY1A P0DUB6 3/20 0.42
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
ATR Q13535 1/20 0.40
CFB P00751 1/20 0.40
DGAT1 O75907 1/20 0.40
SOAT1 P35610 1/20 0.40
KCNH2 Q12809 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7971500 0.86 PTGDR2 (0.49) CHEK2PKN1PKN2PTGDR2RHEB
SCHEMBL7975506 0.82 SLC34A1 (0.39) CHEK2PKN1PKN2PTGDR2RHEB
SCHEMBL7978076 0.82 CHEK2 (0.43) CHEK2PTGDR2RHEBMETAP2METAP1
SCHEMBL16258976 0.81 NPC1 (0.42) CHEK2PTGDR2RHEBATRKDM4E
SCHEMBL20307763 0.81 CHEK2 (0.47) CHEK2PKN1PKN2RHEBAMY1A
SCHEMBL7975522 0.79 KIT (0.44) CHEK2PKN1PKN2RHEBDGAT1
SCHEMBL10140814 0.78 PKN1 (0.50) CHEK2PKN1PKN2PTGDR2RHEB
SCHEMBL7982191 0.78 P2RY6 (0.51) METAP2METAP1KDM4ENPC1ALDH1A1
SCHEMBL3341423 0.78 PKN1 (0.72) CHEK2PKN1PKN2PTGDR2RHEB
SCHEMBL10140860 0.76 PKN1 (0.47) CHEK2PKN1PKN2PTGDR2RHEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 CHEK2 4794/4885PKN1 2799/4885PKN2 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.